Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults

OBJECTIVE: We evaluated safety, antiviral, immunomodulatory and anti-inflammatory properties of aprepitant – a neurokinin 1 receptor antagonist. DESIGN: Phase IB randomized, placebo-controlled, double-blinded study. METHODS: Eighteen patients were randomized (nine to aprepitant and nine to placebo)....

Full description

Saved in:
Bibliographic Details
Published in:AIDS
Main Authors: Tebas, Pablo, Spitsin, Sergei, Barrett, Jeffrey S., Tuluc, Florin, Elci, Okan, Korelitz, James J., Wagner, Wayne, Winters, Angela, Kim, Deborah, Catalano, Renae, Evans, Dwight L., Douglas, Steven D.
Format: Artigo
Language:Inglês
Published: Lippincott Williams & Wilkins 2015
Subjects:
Clinical Science
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4472318/
https://ncbi.nlm.nih.gov/pubmed/25915168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000000638
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items